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Abstract
Background: Complementary and alternative medicine (CAM) use is well documented among
breast cancer patients and survivors, but little evidence is available to describe rates and patterns
of use among women at increased genetic risk of breast cancer.
Methods: A pre-visit telephone interview was conducted to ascertain CAM use among the BRCA
mutation carriers enrolled in a high-risk breast cancer screening study. Participants were asked to
report on their use of thirteen therapies within the year prior to enrollment into the study. Logistic
regression was used to evaluate the association between various factors and CAM use in this
population.
Results: Among the 164 BRCA1 or BRCA2 mutation-positive (BRCA+) women in this analysis, 78%
reported CAM use, with prayer and lifestyle diet being the two most commonly reported
modalities. Many subjects used multiple CAM therapies, with 34% reporting use of three or more
modalities. The most commonly used modalities were mind-body therapies and biologically-based
practices, 61.6% and 51.8%, respectively. High-risk women were more likely to use CAM if they
were older, more educated, more worried about ovarian cancer risk, or had a previous cancer
diagnosis.
Conclusion: This study suggests that the prevalence of CAM use is high among BRCA mutation
carriers, with frequency of use comparable to that of breast cancer patients and survivors. Given
the high prevalence of CAM use in our subjects, especially biologically-based therapies including
herbal supplements, whose safety and efficacy in relation to cancer risk are unknown, our study
suggests that future research is necessary to clarify these risks, and that it is important for providers
to inquire about and to discuss the pros and cons of CAM use with their BRCA+ patients.
Background
Complementary and alternative medicine (CAM)
includes a collection of therapies, practices, and products
that are not considered to be part of conventional medical
practice [1]. The National Center for Complementary and
Alternative Medicine (NCCAM) divides CAM therapies
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into five domains, recognizing that overlap exists. They
include (with examples): biologically-based practices
(herbs, diets), mind-body medicine (prayer, meditation,
yoga), energy healing (Reiki, therapeutic touch), manipu-
lative and body based practices (chiropractic care, mas-
sage), and whole medical systems (traditional Chinese
medicine, Ayurveda). Use of CAM escalated in the United
States during the 1990's, with an estimated $36 to $47 bil-
lion spent on these modalities in 1997 alone. In addition,
several studies have shown that CAM is most commonly
used in conjunction with conventional medical interven-
tions [2,3].
The 2002 National Health Interview Survey (NHIS) of
31,044 US adults, of whom more than 17,000 were
women, provides the most recent CAM use data for the
general population. In that survey, CAM use was greater
among women than men, with sixty-nine percent of
women reporting CAM use within the 12 months prior to
survey completion. Prayer was the most commonly used
modality. When prayer for health reasons was excluded,
the prevalence of CAM use among women decreased to
40%. Higher levels of CAM use were associated with
increased education, higher income, and poorer health
status. In general, women between 50–59 years of age
comprised the sub-group with the highest rates of use for
most CAM modalities, except for prayer, which continued
to increase with advancing age [2,4].
Several studies have shown that cancer patients and survi-
vors are more likely to use CAM than unaffected individ-
uals in the general population, with up to 83% reporting
CAM use [5-8]. Furthermore, women with a current or
previous diagnosis of breast cancer have been reported to
use CAM more frequently than individuals diagnosed
with other cancers [9]. Self-reported motivations for CAM
use among recently-diagnosed patients include desires to
improve quality of life, enhance immune function, and
actively participate in self-care [6,10]; higher levels of anx-
iety and depression have been associated with higher rates
of CAM use among cancer patients and survivors [11-13].
While there is an extensive literature regarding CAM use
among breast cancer patients, much less is known about
its use among women at high genetic risk of developing
breast cancer. In a previous study of CAM use within a
cohort of women undergoing genetic counseling and test-
ing for germline mutations in BRCA1/2 genes, cancer sur-
vivors reported significantly more CAM use than
unaffected women [14]. A follow-up to that study showed
that BRCA+ women were more likely to be using CAM one
year after disclosure of their genetic test result, compared
with usage rates prior to genetic testing [15].
Women at increased genetic risk of breast and ovarian
cancer face difficult decisions when choosing the optimal
strategy to manage their cancer risk. Their decisions are
often based on personal beliefs, attitudes, and experi-
ences, as expressed by their cancer risk perception and
worry [16-20]. Furthermore, high-risk women who
choose salpingo-oophorectomy as an ovarian cancer risk-
reducing option must also face medical decisions regard-
ing the management of postmenopausal symptoms
related to surgical menopause. For the general population
and breast cancer survivors, this often includes taking
herbal supplements, such as soy products, whose safety
and efficacy are unproven [21,22]. With the increased
prevalence of CAM usage in the general population, it is
important to identify patterns of use among high-risk
women to promote informed medical decision-making
and to improve the quality of care that these patients
receive. In this study, we comprehensively described and
analyzed CAM use in women with known BRCA1  or
BRCA2  mutations enrolled in a high-risk breast cancer
screening study.
Methods
The Clinical Genetics Branch Breast Imaging Screening
Study in Women at High Genetic Risk of Breast Cancer:
Annual Follow-up Study (NCI protocol 01-C-0009) is
aimed at evaluating breast cancer screening modalities
among women who are genetically predisposed to devel-
oping breast cancer. The study consists of four consecutive
annual evaluations including mammogram, breast MRI,
clinical breast examination, transvaginal ultrasound, CA-
125 and breast ductal lavage. As part of this protocol, par-
ticipants were asked to complete a self-administered ques-
tionnaire and a telephone questionnaire prior to their first
study visit. Participants were eligible for the study if they
were between 25 and 56 years of age, had a known BRCA1
or BRCA2 mutation, or were first- or second-degree rela-
tives of a known BRCA mutation-positive family member.
Women younger than 25, but within 5 years of the age at
diagnosis of the youngest family member with a heredi-
tary breast-ovarian cancer syndrome-associated tumor,
were also eligible.
Exclusion criteria included pregnancy or lactation within
6 months of enrollment, abnormal CA-125 level, bilateral
breast cancer, previous bilateral mastectomy or bilateral
radiation therapy, weight over 136 kg, or allergy to gado-
linium. Individuals with a personal history of ductal car-
cinoma in situ (DCIS), Stage I, or Stage IIA breast cancer
were eligible provided that at least 6 months had elapsed
since completing primary therapy (surgery, radiation, or
chemotherapy). Other exclusion criteria included a per-
sonal history of ovarian cancer (any stage); breast cancer
(stage IIB or higher); DCIS, Stage I or Stage IIA breast can-
cer with a relapse after primary treatment; or any otherBMC Complementary and Alternative Medicine 2008, 8:17 http://www.biomedcentral.com/1472-6882/8/17
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invasive cancer except non-melanoma skin cancer or cer-
vical carcinoma in situ, unless relapse-free for 5 years prior
to the time of enrollment. Informed consent was obtained
from all participants, and a total of 200 women were
enrolled onto 01-C-0009 between June 2002 and Febru-
ary 2007. A secondary study objective of the study was to
determine the rates of CAM use in high-risk women
enrolled in this breast cancer screening study related to
various participant characteristics and screening behav-
iors. Of the participants in the Breast Imaging Screening
Study, 164 women who know their BRCA+  status and
completed their CAM questionnaire were included in this
analysis.
Demographics
Demographic information, including age, race (white,
non-white), marital status (single, married/steady rela-
tionship, separated/divorced), number of children (0,
≥1), education (high school or less, college and beyond),
and personal cancer history, was obtained through the
pre-visit questionnaires.
Complementary and Alternative Medicine Use
Complementary and alternative medicine data were
obtained through the pre-visit telephone interview, which
was completed prior to the first study visit. Participants
were asked to answer "yes" or "no" to the use of each of
thirteen CAM therapies (acupuncture, meditation, relaxa-
tion techniques, yoga, massage therapy, imagery, spiritual
healing or prayer, lifestyle diet, herbal medicine, homeo-
pathic treatment, energy healing, biofeedback, and hyp-
nosis) within the previous year. No standard examples of
these modalities were provided by the interviewer, and no
further details regarding frequency, duration, or purpose
of use were elicited. Participants were also given the
opportunity to report the use of additional therapies. For
data analysis purposes, the individual CAM therapies were
further grouped by the defined NCCAM domains: biolog-
ically-based practices (herbal medicine, lifestyle diet);
mind-body medicine (spiritual healing or prayer, medita-
tion, yoga or tai chi, relaxation techniques, biofeedback,
imagery, hypnosis); energy healing, manipulative and
body-based practices (massage therapy); and alternative
medical systems (homeopathic treatment, acupuncture).
Perceived Cancer Risk
Perceived breast and ovarian cancer risk was assessed for
each cancer with the survey question: "In your opinion,
compared to other women your age, what are your
chances of getting breast/ovarian cancer in your lifetime?"
Participants responded with categorical options: "Much
less," "A little less," "About the same," "A little more" or
"Much more," coded on a 1–5 scale. For the current anal-
ysis, responses were dichotomized to average or below
average (codes 1–3) and above average (codes 4,5) risk
perceptions [16]. Individuals who chose not to answer the
question were excluded from the cancer risk perception
analysis.
Cancer Worry
Cancer worry was determined using three validated ques-
tions from the Lerman Cancer Worry Scale [23,24], relat-
ing to frequency of thoughts of getting either breast or
ovarian cancer and their impact on mood and daily activ-
ities: "During the past month, how often have you
thought about your own chances of getting breast/ovarian
cancer; how often have thoughts about your chances of
getting  breast/ovarian  cancer affected your mood; how
often have thoughts about breast/ovarian cancer affected
your ability to perform your daily activities?" Participants
responded with categorical options: "Not at all or Rarely,"
"Sometimes," "Often," "A lot," coded on a 1–4 scale. The
average score was calculated for each cancer to determine
their level of cancer worry. Individuals who chose not to
answer the questions were excluded from the cancer worry
analysis.
Depression
Depression was measured using the 20 question Center
for Epidemiologic Studies Depression (CES-D) Scale, a
short self-report instrument designed to measure depres-
sive symptoms in the general population, emphasizing
depressed mood, the major affective component of
depression [25]. Each question was scored from 0 to 3
based on the frequency of occurrence within the past
week, with responses then summed, for a total possible
score ranging from 0 to 60. We grouped the scores into
<16 and ≥ 16, since a score of ≥ 16 is indicative of clinical
depression [25]. For individuals with four or fewer miss-
ing responses, a person-mean imputation technique
based on the existing responses was utilized to develop a
total score. The mean value of the individual's completed
items is substituted into the missing items to calculate a
total CES-D score as previously described [26]. Individu-
als with >4 missing responses were excluded from the
depression analysis.
Screening Behavior
Participants provided detailed information on how fre-
quently they performed cancer screening activities before
study enrollment. For mammography and transvaginal
ultrasound (TVU), we dichotomized participants as either
"following" or "not following" appropriate screening
guidelines (monthly breast self exam (BSE), annual mam-
mography, annual TVU) based on self-reported screening
frequency [16,27]. The date of mutation status disclosure
was defined as the time from which appropriate screening
practices should have been followed. Individuals who
screened more frequently than recommended guidelines
were considered to be following guidelines. Women whoBMC Complementary and Alternative Medicine 2008, 8:17 http://www.biomedcentral.com/1472-6882/8/17
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reported having bilateral oophorectomy (n = 69) were
excluded from the TVU data analysis.
Statistical Analysis
For comparison between CAM users and non-users, Chi-
square and Fisher's Exact tests were used as appropriate for
categorical variables, and Wilcoxon rank-sum test was
used for continuous variables. We used logistic regression
to evaluate the association between various factors and
CAM use. Factors with a p-value of ≤ 0.20 in the univariate
analysis were included in the final multivariate logistic
regression model. Factors with a two-tailed p-value of
≤0.05 in the multivariate model were considered to be sta-
tistically significant. All statistical analyses were con-
ducted using SPSS 15.0.
Results
Of 165 BRCA+ women who knew their mutation status
prior to enrolling in the Breast Imaging Screening Study,
164 answered the pre-visit telephone CAM questionnaire
and were included in this analysis. The cohort was highly-
educated (92.7% attending college); predominately white
(97.6%); most were married (72%); over half reported
having children (54.3%); and 17.7% had a personal his-
tory of cancer prior to study entry.
The overall CAM use rate in our BRCA+ population was
78% (128/164), with an average of 2.3 CAM therapies
used per person. Thirty-four percent of the cohort
reported having used three or more CAM therapies within
the past year. As shown in Figure 1A, only 15 (9.1%)
BRCA+ women reported prayer as the sole CAM therapy
used. If spiritual healing/prayer are excluded, 68.9% of
participants had used CAM in the previous year. Spiritual
healing/prayer and lifestyle diet were the most commonly
reported modalities (48.8% and 48.2%, respectively). Fig-
ure 1B shows CAM use grouped by NCCAM domains: bio-
logically-based practices (herbal medicine, lifestyle diet);
mind-body medicine (spiritual healing or prayer, medita-
tion, yoga or tai chi, relaxation techniques, biofeedback,
imagery, hypnosis); energy healing, manipulative and
body-based practices (massage therapy); and alternative
medical systems (homeopathic treatment, acupuncture).
Mind-body therapies and biologically-based practices
were the most commonly used domains (61.6% and
51.8%, respectively). However, if prayer is excluded from
the computations, biologically-based practices become
the most prevalent modality.
There were significant positive associations between CAM
use and several demographic, health-related, and psycho-
social variables (Tables 1 and 2). Higher education (p =
0.015), a previous cancer diagnosis (p = 0.006), and older
age (p = 0.007) were all associated with increased CAM
use. Although the overall scores were not high (median =
1.33), higher ovarian cancer worry scores were statistically
significantly associated with increased CAM use (p =
0.011) (Table 2). These findings did not change when the
ovarian cancer worry analysis was restricted to the 95
women with intact ovaries (data not shown); therefore, all
women were included in the multivariate regression anal-
ysis. Among the demographic indicators, race (p = 1.00),
number of children (p = 0.52), and marital status (p =
0.91) were not associated with CAM use, and neither were
the health-related behaviors of breast or ovarian cancer
screening, nor the psychosocial variables depression, per-
ceived cancer risk, and breast cancer worry.
Factors with p ≤ 0.20 (age, education, previous cancer
diagnosis, ovarian cancer worry, breast cancer worry, and
BSE) were included in the multivariate logistic regression
model. Odds ratios and 95% confidence intervals are pre-
sented in Table 3. Age, higher education, previous cancer
diagnosis, and increased ovarian cancer worry remained
statistically significantly associated with CAM use (p ≤
0.05). Previous cancer diagnosis showed the strongest
association with increased CAM use; women with any pre-
vious cancer were 17 times more likely to use CAM than
unaffected women. Multivariate analysis showed a weak,
yet statistically significant, inverse association between
frequency of BSE and CAM use; women who did BSE less
than once a month were more likely to use CAM.
Since a previous cancer diagnosis was highly-associated
with CAM use in our population, a finding previously-
reported in the general population literature, we repeated
our analyses after excluding the women with a previous
cancer diagnosis. The overall patterns of the CAM thera-
pies used remained unchanged (data not shown), with
the exception of lifestyle diet being more commonly used
than spiritual healing/prayer (47.4% and 44.4%, respec-
tively) compared with 48.2% and 48.8%, respectively in
the previous analysis. When spiritual healing/prayer was
excluded, overall CAM use was 65.2% compared to 68.9%
when all BRCA+ women were included in the analysis.
Age, education, previous cancer diagnosis, ovarian cancer
worry, breast cancer worry, and BSE all had p ≤ 0.20 in the
univariate analyses again and were included in the multi-
variate logistic regression model. Ovarian cancer risk per-
ception was also included in the multivariate analyses
with p = 0.15. As was the case with the previous analysis,
age, higher education, ovarian cancer worry, and BSE
remained statistically significantly associated with CAM
use (p ≤ 0.05), with similar odds ratios. Ovarian cancer
risk perception was no longer statistically significant.
Discussion
Our study provides the largest, most comprehensive
descriptive analysis of CAM use among BRCA mutationBMC Complementary and Alternative Medicine 2008, 8:17 http://www.biomedcentral.com/1472-6882/8/17
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Patterns of CAM Use in BRCA+ Women Figure 1
Patterns of CAM Use in BRCA+ Women.
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carriers who are at increased genetic risk of breast and
ovarian cancer, and who had undergone risk assessment
and counseling prior to enrollment. Compared with data
from women in the general population [4], the high-risk
women enrolled in our cohort were more likely to use
CAM (78% vs. 69%), a rate which is comparable to that
reported for breast cancer patients and survivors [5-8].
When prayer is excluded, only 40% of women in the gen-
eral population used CAM, compared with 68.9% of the
BRCA+ women in our study [4]. Therefore, although
prayer was also the most commonly used CAM modality
in our population, in contrast to the pattern of use
observed in the general population, it was commonly
used in addition to other modalities.
CAM use in our cohort was associated with older age,
higher education level, and higher levels of ovarian cancer
worry. A previous cancer diagnosis showed the strongest
association with increased CAM use in our BRCA+ popu-
lation, consistent with reports based on general popula-
Table 1: Associations Between CAM Use and Demographic, Psychosocial and Health-related Categorical Predictor Variables in BRCA+ 
Women
Variable CAM User (%) CAM Nonuser (%) p
Education
High School or Less 6 (4.7) 6 (16.7) 0.015
Some College and Beyond 122 (95.3) 30 (83.3)
Race/Ethnicity
White 125 (97.7) 35 (97.2) 1.00
Non-White 3 (3.3) 1 (2.8)
Children
0 56 (43.8) 17 (50.0) 0.52
≥1 72 (56.3) 17 (50.0)
Marital Status
Single 27 (21.3) 7 (19.4) 0.91
Married/Steady Partner 91 (71.7) 27 (75.0)
Separated/Divorced 9 (7.1) 2 (5.6)
Previous Cancer History*
Yes 28 (21.9) 1 (2.8) 0.006
No 100 (78.1) 35 (97.2)
CES-D Score
Depressed 25 (19.7) 6 (16.7) 0.68
Not Depressed 102 (80.3) 30 (83.3)
Breast Cancer Risk Perception
Average or Below Average Risk 3 (2.4) 1 (2.9) 1.00
Above Average Risk 121 (97.6) 33 (97.1)
Ovarian Cancer Risk Perception
Average or Below Average Risk 34 (27.4) 11 (32.4) 0.57
Above Average Risk 90 (72.6) 23 (67.6)
Breast Self Exam
Less than Once per Month 58 (46.0) 11 (31.4) 0.12
At Least Once per Month 68 (54.0) 24 (68.6)
Mammography
Not Following Guidelines 25 (19.5) 10 (27.8) 0.29
Following Guidelines 103 (80.5) 26 (72.2)
Transvaginal Ultrasound *limited to 95 women with ovaries
Not Following Guidelines 22 (29.3) 4 (20.0) 0.57
Following Guidelines 53 (70.7) 16 (80.0)
* Number of cancers by site: breast cancer = 23 (two with multiple primaries 1 = melanoma, 1 = basal cell carcinoma), ovarian cancer = 1, 
melanoma = 1, thyroid = 1, vaginal clear cell adenocarcinoma = 1, basal cell carcinoma = 2
Table 2: CAM Use and Demographic, Psychosocial and Health-related Continuous Predictor Variables in BRCA+ Women
CAM User Median (Range) CAM Nonuser Median (Range) p
Age 41.0 (22.0–55.0) 35.0 (23.0–55.0) 0.007
Breast Cancer Worry 1.67 (1.00–3.67) 1.33 (1.00–2.67) 0.18
Ovarian Cancer Worry 1.33 (1.00–3.67) 1.00 (1.00–2.33) 0.011BMC Complementary and Alternative Medicine 2008, 8:17 http://www.biomedcentral.com/1472-6882/8/17
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tion samples [5-8]. In a previous report on high-risk
women, cancer survivors reported more CAM use than
unaffected women; however, all univariate and multivari-
ate analyses in that study were conducted separately for
these groups [14]. Since our sample included only a small
number of participants with a previous cancer diagnosis,
analyzing CAM use stratified by previous cancer history
would have had limited statistical power. As an alterna-
tive, we performed our analyses excluding the women
with a previous cancer diagnosis, and found no meaning-
ful differences in results.
Previous studies have reported conflicting evidence for the
association between age and CAM use both in the general
population and in breast cancer patients and survivors
[2,6,28,29], while other studies have shown no associa-
tion between age and CAM use [15,30]. Some of this dis-
cordance may be due to the manner in which age is
dichotomized in different studies. The age group with the
most extensive CAM use in the general population was
between 50–59 years [2]. In our study, CAM use increased
with age, but the oldest subject in our cohort was only 55.
Thus, we were not able to evaluate CAM use in older
women.
This study showed no association between CAM use and
perceived cancer risk (breast and ovarian) or breast cancer
worry. CAM users tended to be more worried about ovar-
ian cancer, but overall the reported levels of breast and
ovarian cancer worry were low. Higher rates of CAM use
have been associated with increased levels of depression
in cancer survivors and individuals with chronic illness in
some studies [2,13,31], a finding we did not corroborate.
These results may be related to the homogeneity of our
study participants, all of whom have been informed of
their increased cancer risk through genetic counseling,
knew themselves to be BRCA  mutation-positive; have
chosen breast cancer screening rather than prophylactic
mastectomy to manage their risk; and, for the majority,
have not developed a BRCA-related malignancy. These
characteristics, in the aggregate, may yield a group of
women which is less worried about developing cancer
than the more heterogeneous groups of high-risk women
who have been studied previously.
Prior reports have suggested that high-risk women report
better health maintenance practices than do women from
the general population [14,16]. Therefore, we evaluated
potential associations between CAM use and cancer
screening practices for breast and ovarian cancer, covari-
ates which have not been previously examined. The
majority of our study participants followed recommended
screening guidelines. The only significant, although weak,
association that we found was that women who did BSE
less than once a month were more likely to use CAM.
Limitations to our study include the reliance on self-
reported data regarding CAM use. Participants were not
provided examples for each of the thirteen modalities,
and thus may have interpreted modalities such as lifestyle
diet differently. Furthermore, we did not collect data on
duration and frequency of use for each CAM, nor did we
elicit information regarding specific motives for CAM use
such as cancer prevention. Such data might have provided
further insight into the lifestyle choices that our subjects
have made in their efforts to prevent breast and ovarian
cancer, and cope with the increased stress related to know-
ing that they are at high risk of malignancy. Another lim-
itation of the study is a relatively small sample size both
overall and of cancer survivors, providing for minimal sta-
tistical power for some analyses. Finally, our study popu-
lation should not be considered representative of all
BRCA  mutation carriers, since it was comprised of
research volunteers who were almost exclusively white
and highly-educated, both characteristics that are associ-
ated with higher rates of CAM use in the general popula-
tion.
Conclusion
We have documented that the rates of CAM use in our
cohort of BRCA+ women, most of whom have never
developed cancer, are roughly equivalent to the rates
reported for women being treated for, or having survived,
breast cancer, and seem to be higher than the rates
reported for women from the general population. Further
investigation will be required to better understand the
intensity of, and motivations for, CAM use, as well as the
relationships between CAM use, conventional screening
practices, and cancer risk and worry in BRCA+ women.
Data from a more representative sample of all mutation
carriers would likely be very informative as well. However,
given the high prevalence of CAM use in our subjects,
especially the predominance of biologically-based thera-
pies, which might pose a greater risk of unanticipated
adverse effects, our study suggests that it is important for
providers to inquire about, and to discuss the pros and
cons of CAM use, with their BRCA+ patients [32].
Table 3: Multivariate Associations Between CAM Use and 
Predictor Variables in BRCA+ Women
Odds Ratio (95% CI) p
Education 10.3 (2.0–53.8) .006
Personal Cancer History 17.1 (1.5–191.4) .021
Breast Self Exam 0.3 (0.1–0.8) .017
Age 1.1 (1.0–1.1) .016
Breast Cancer Worry 1.0 (0.4–2.4) .958
Ovarian Cancer Worry 7.9 (1.7–38.1) .009BMC Complementary and Alternative Medicine 2008, 8:17 http://www.biomedcentral.com/1472-6882/8/17
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